Cardiovascular — Operating Income (Loss), Adjusted
Boston Scientific Cardiovascular — Operating Income (Loss), Adjusted decreased by 7.5% to $1.05B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 26.7%, from $829.00M to $1.05B. Over 3 years (FY 2022 to FY 2025), Cardiovascular — Operating Income (Loss), Adjusted shows an upward trend with a 34.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase reflects improved operational performance, pricing power, or cost management within the cardiovascular segment.
Detailed definition
This metric represents the profitability of the cardiovascular segment after excluding non-recurring or non-operational...
Peer comparison
Equivalent to 'Adjusted Segment Operating Profit' reported by major medical technology competitors.
bsx_segment_cardiovascular_operating_income_loss_adjustedHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $446.00M | $446.00M | $446.00M | $446.00M | $570.25M | $570.25M | $570.25M | $570.25M | $674.00M | $782.00M | $862.00M | $829.00M | $1.05B | $1.07B | $1.14B | $1.05B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +27.9% | +0.0% | +0.0% | +0.0% | +18.2% | +16.0% | +10.2% | -3.8% | +27.0% | +1.1% | +6.6% | -7.5% |
| YoY Change | — | — | — | — | +27.9% | +27.9% | +27.9% | +27.9% | +18.2% | +37.1% | +51.2% | +45.4% | +56.2% | +36.2% | +31.7% | +26.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's cardiovascular — operating income (loss), adjusted?
- Boston Scientific (BSX) reported cardiovascular — operating income (loss), adjusted of $1.05B in Q4 2025.
- How has Boston Scientific's cardiovascular — operating income (loss), adjusted changed year-over-year?
- Boston Scientific's cardiovascular — operating income (loss), adjusted increased by 26.7% year-over-year, from $829.00M to $1.05B.
- What is the long-term trend for Boston Scientific's cardiovascular — operating income (loss), adjusted?
- Over 3 years (2022 to 2025), Boston Scientific's cardiovascular — operating income (loss), adjusted has grown at a 34.1% compound annual growth rate (CAGR), from $1.78B to $4.30B.
- What does cardiovascular — operating income (loss), adjusted mean?
- The core operating profit generated by the cardiovascular business segment, excluding one-time adjustments.